|
WO2020023389A1
|
|
Reduced exposure compositions modulating therapeutic targets
|
|
WO2020023387A1
|
|
Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
|
|
WO2019143971A2
|
|
Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure
|
|
WO2019126270A1
|
|
Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure
|
|
WO2019112964A1
|
|
Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure
|
|
WO2018175315A1
|
|
Polymer conjugates of staurosporine derivatives having reduced exposure
|
|
EP3621657A1
|
|
Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
|
|
WO2018175301A1
|
|
Polymer conjugate of montesanib with reduced exposure
|
|
EP3600440A1
|
|
Reduced exposure conjugates modulating therapeutic targets
|
|
WO2018175302A1
|
|
Polymer conjugates targeting c-src with reduced exposure
|
|
US2018071024A1
|
|
Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles
|
|
US2014316387A1
|
|
Ultrasound delivery of nanoparticles
|
